Research Analysts Issue Forecasts for PRQR FY2026 Earnings

ProQR Therapeutics N.V. (NASDAQ:PRQR) – Stock analysts at HC Wainwright dropped their FY2026 earnings per share (EPS) estimates for ProQR Therapeutics in a research report issued on Wednesday, May 13th. HC Wainwright analyst A. Ghosh now expects that the biopharmaceutical company will post earnings of ($0.44) per share for the year, down from their previous estimate of ($0.43). The consensus estimate for ProQR Therapeutics’ current full-year earnings is ($0.53) per share.

ProQR Therapeutics (NASDAQ:PRQR) last issued its quarterly earnings data on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) EPS for the quarter, hitting the consensus estimate of ($0.15). ProQR Therapeutics had a negative return on equity of 65.89% and a negative net margin of 255.83%.The company had revenue of $2.35 million during the quarter, compared to analyst estimates of $5.19 million.

Several other brokerages have also commented on PRQR. Oppenheimer started coverage on ProQR Therapeutics in a report on Thursday, March 12th. They set an “outperform” rating and a $9.00 price objective for the company. Citigroup reissued a “market outperform” rating on shares of ProQR Therapeutics in a report on Friday, March 13th. Chardan Capital reissued a “buy” rating and set a $4.00 price objective on shares of ProQR Therapeutics in a report on Thursday, April 9th. Wall Street Zen raised ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday, March 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of ProQR Therapeutics in a research report on Tuesday, April 21st. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $7.25.

ProQR Therapeutics Trading Down 2.9%

Shares of NASDAQ PRQR opened at $1.65 on Friday. ProQR Therapeutics has a 12 month low of $1.33 and a 12 month high of $3.10. The firm has a market capitalization of $173.84 million, a price-to-earnings ratio of -3.59 and a beta of 0.08. The business has a 50-day moving average of $1.70 and a 200-day moving average of $1.86.

Institutional Trading of ProQR Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Osaic Holdings Inc. lifted its position in ProQR Therapeutics by 59.6% in the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 4,500 shares during the last quarter. Guggenheim Capital LLC bought a new position in shares of ProQR Therapeutics during the fourth quarter valued at approximately $35,000. Moody Lynn & Lieberson LLC bought a new position in shares of ProQR Therapeutics during the fourth quarter valued at approximately $50,000. Invesco Ltd. bought a new position in shares of ProQR Therapeutics during the fourth quarter valued at approximately $51,000. Finally, Fifth Third Bancorp bought a new position in shares of ProQR Therapeutics during the third quarter valued at approximately $64,000. Institutional investors own 32.65% of the company’s stock.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.